Curated News
By: NewsRamp Editorial Staff
September 23, 2026
NeuroThera Expands U.S. Patents for Psychedelic-PEA Combinations
TLDR
- NeuroThera Labs expands U.S. patent portfolio with LSD, ketamine, and ibogaine combinations, securing a strategic advantage in psychedelic therapeutics.
- NeuroThera's PEA technology combines with psychoactive compounds through a collaboration with Clearmind Medicine, targeting mental health and substance use disorders.
- NeuroThera and Clearmind aim to bring safer, more effective treatments to market for depression, PTSD, and substance use disorders, improving lives.
- NeuroThera Labs has published three U.S. patent applications for combining PEA with LSD, ketamine, and ibogaine for potential therapeutic uses.
Impact - Why it Matters
This news matters because it signals a potential breakthrough in treating some of the most pressing mental health crises, including depression, PTSD, and substance use disorders, which affect millions worldwide and often resist conventional treatments. By combining PEA with psychedelic compounds like LSD, ketamine, and ibogaine, NeuroThera and Clearmind are exploring a novel therapeutic approach that could lead to safer, more effective options. The expansion of their patent portfolio not only strengthens their intellectual property position but also accelerates the path toward clinical trials, offering hope for patients who have not responded to existing therapies. As the demand for innovative mental health solutions grows, this collaboration could pave the way for a new class of treatments, potentially transforming care for neuropsychiatric and addiction disorders.
Summary
NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company, has announced a significant expansion of its U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. The collaboration has resulted in three newly published U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines, including palmitoylethanolamide (PEA), NeuroThera’s proprietary technology. These applications target potential therapeutic uses for mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.
This development builds on previously announced intellectual property from the collaboration, including a U.S. patent application for combining MDMA with N-acylethanolamines to potentially treat PTSD, anxiety, and eating disorders. The maturation of this patent portfolio highlights the broad potential of NeuroThera’s PEA technology when paired with psychoactive compounds, supporting the development of novel therapies for neuropsychiatric and substance use disorders. NeuroThera and Clearmind are dedicated to advancing safer, more effective treatments for rapidly growing mental health conditions, with a focus on enhancing the intellectual property supporting these programs.
As a clinical-stage company, NeuroThera Labs focuses on developing therapeutics for central nervous system disorders and other underserved conditions. The original release can be viewed on www.newmediawire.com. For further information, contact Michal Efraty, IR Manager, at [email protected].
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, NeuroThera Expands U.S. Patents for Psychedelic-PEA Combinations
